Effects of erdosteine on serum biomarker concentrations at COPD exacerbation

Trial Profile

Effects of erdosteine on serum biomarker concentrations at COPD exacerbation

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2013

At a glance

  • Drugs Erdosteine (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics
  • Sponsors Edmond Pharma
  • Most Recent Events

    • 10 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
    • 10 Sep 2013 Primary endpoint 'C-reactive-protein' has been met.
    • 23 Mar 2011 Primary endpoint 'Leukotriene-E4-levels' has been met
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top